OR WAIT null SECS
December 11, 2017
FDA has accepted for review Eli Lilly and Company’s biologic drug candidate that is in development for treating migraine.
December 08, 2017
Gilead Sciences will acquire Cell Design Labs to further cell-therapy research and development efforts.
December 04, 2017
FDA has approved Mylan’s biosimilar to Roche’s blockbuster anti-cancer biologic, Herceptin.
The acquisition deepens Astellas’ involvement in the development of a pipeline of therapeutics focused on mitochondrial function.
December 01, 2017
The company has opened a new California facility that, combined with its existing site in Foster City, CA, will quadruple its laboratory footprint for gene therapy products.
November 28, 2017
The joint venture will focus on the discovery, development, and commercialization of potential new drugs for the global market as well as speed delivery of new medicines to China.
November 27, 2017
In the wake of generic-drug pricing pressure and declining revenues, Teva has restructured its commercial business and made executive leadership changes.
November 20, 2017
The opnME.com platform offers scientists access to best-in-class molecules supported by comprehensive data packages.
Ontruzant is the first biosimilar of Roche’s Herceptin (trastuzumab) to be approved in Europe.
The agency has approved a biologic-based new molecular entity for treating hemophilia A and has expanded the indication for a leukemia drug to now treat a common form of non-Hodgkin lymphoma.